NLite(TM) Laser for Wrinkle Reduction Now Available
COSTA MESA, Calif., Nov. 1 /PRNewswire/ -- ICN Pharmaceuticals, Inc.
announced today that its innovative NLite(TM) laser for wrinkle reduction is
now available in 42 states in the U.S.
More than 500 U.S. physicians have received specific training on the new
laser, which is distributed for ICN by Medical Alliance, Inc.
The NLite laser is a new approach to wrinkle reduction that uses yellow
light to stimulate the body's own collagen layer to reduce wrinkles and fine
lines gradually. It is the thinning of the collagen layer due to aging or the
effects of the sun that causes wrinkles and fine lines.
In clinical trials, patients experienced a visible reduction in wrinkles
beginning about 30 days after treatment. Improvements continued up to 90
days. Treatment with the NLite laser resulted in no side effects, and patients
reported no pain during the procedure.
"The real improvement that this laser brings my patients is the fact that
the procedure is painless, requiring no anesthesia or follow-up care," said
Nita Patel, M.D., a leading cosmetic dermatologist in Marina Del Rey,
California. "I can perform the procedure in about 20 minutes. The patient can
return to work or resume his or her daily routine with no discomfort and no
one the wiser."
Mark Taylor, Executive Vice President, ICN Pharmaceuticals North American
Division, said, "Because there is no lengthy recovery period as there is with
other procedures, we believe this laser will make it possible for many more
individuals, both men and women, to take advantage of laser wrinkle reduction.
Because the effects are gradual, we think that men, who are sometimes hesitant
to let people know they are undergoing cosmetic procedures, will choose NLite.
Some patients may elect to repeat the procedure once or twice, but we believe
that many will be satisfied with the results from only one treatment."
The NLite laser was developed by Professor Marc Clement and Mike Kiernan,
Ph.D., of ICN Photonics LTD, a newly acquired division of ICN Pharmaceuticals,
Inc. It has been available in the United Kingdom and Europe since early 2000
and received approval for marketing from the U.S. Food and Drug Administration
in August, 2000.
NLite is administered in a physician's office under the care of a
physician.
ICN manufactures, markets and distributes a broad range of prescription
and non-prescription pharmaceuticals, including anti-infectives, anti-virals,
and anti-cancer drugs, under the ICN brand name.
Among its dermatology product portfolio, ICN makes and markets
Oxsoralen(R) for severe psoriasis, Efudex(R) (fluorouracil) for actinic
keratosis (a precancerous skin condition), Kinerase(R) (N6-furfuryladenine)
for photoaging, the Gly-derm(R) (line of cosmeceuticals, and the recently
introduced Glyquin(TM) for hyperpigmentation.
Additional information is also available on the corporate website at
icnpharm.com.
THE 'SAFE HARBOR' STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995. This press release contains forward-looking statements that
involve risks and uncertainties including, but not limited to, projections of
future sales, operating income, subsidiary reorganization, regulatory approval
processes, operations in countries with unstable economies, the progress of
FDA reviews, and other risks detailed from time to time in the Company's
Securities and Exchange Commission filings.
SOURCE ICN Pharmaceuticals, Inc.
-0- 11/01/2000
/CONTACT: Marsha Wilson of Burson-Marsteller, 202-530-4609, for ICN
Pharmaceuticals, Inc./
/Web site: icnpharm.com
CO: ICN Pharmaceuticals, Inc.; Medical Alliance, Inc.
ST: California
IN: MTC
SU: PDT
*** end of story *** |
